Zacks Investment Research | Mar 18, 2020 09:44PM ET
To meet the growing need for ventilators at the onset of the Coronavirus outbreak, Medtronic plc (NYSE:MDT) has planned to more than double its capacity to manufacture and supply ventilators. The decision came on the heels of the company recognizing heightening demand massively outstripping supply for this device in battling COVID-19 infections.
When all other major business segments of the company are facing recessionary hurdles during such uncertain times, Medtronic’s latest initiative seems strategic. This is anticipated to boost its Minimally Invasive Therapies Group revenues in the upcoming period.
While battling the pandemic, ventilators are needed to treat coronavirus-affected patients with severe respiratory illness. Per Medtronic, ventilator, while performing the functions of supplying oxygen and simulating the actions of breathing, allows the lungs of the patient to rest and recover.
Per the company, it has ventilators for a wide range of care settings within its respiratory care setting, including the acute segment (in-hospital patients in intensive care units, emergency departments or on the general care floors) and the sub-acute segment (out of hospital, long-term care facilities or home-ventilated patients).
The Ramp-Up Initiative
In Galway, Ireland, Medtronic manufactures its Puritan Bennett 980 (PB 980) and Puritan Bennett 840 (PB 840) ventilators. Both PB 980 and PB 840 ventilators are designed for critically ill patients in high acuity setting and are expected to be suitable for COVID-19 patients (with or without an underlying health issue).
At present, in this manufacturing facility, there are more than 250 employees dedicated to ventilator manufacturing and the company plans to more than double that number. Additional staff is currently being shifted from other Medtronic sites to support this ramp-up activity.
Considering the intensity of the current turbulence, the company is also prioritizing high risk/high need areas for ventilator allocation on a weekly basis for efficient global distribution through supply chains.
Share Price Performance
Meanwhile, shares of Medtronic underperformed the Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.